Abstract: Disclosed are means of preventing, reducing and/or treating pregnancy associated complications by administration of Noble Gas mixtures, directly by inhalation, or by other means of direct or indirect introduction, with the intended effect of reducing immunological/inflammatory events associated with said complications. In one embodiment the invention teaches the modulation of the maternal-fetal unit from a Th1/Th17 predisposition towards a Th2/Treg environment by inhalation of a combination of 30% xenon gas admixed with air, or combinations of medical grade oxygen and nitrogen.

Abstract: A multi-function nitrous oxide system is disclosed for producing breathing air. The system includes a nitrous oxide storage container and a nitrous oxide conversion element connected with the nitrous oxide storage container. The nitrous oxide conversion element is downstream from the nitrous oxide storage container and produces hot fluid. The system includes a breathing air storage container connected with the nitrous oxide conversion element downstream from the nitrous oxide conversion element.

Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that include an anionic drug and exhibit desired characteristics such as stability, preservation efficacy, desired pH, desired osmolality, combinations thereof or the like.

Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Abstract: This relates to a method to generate a mixture of Hydrogen Peroxide gas and a Carrier gas, consisting in passing a dry Carrier gas through a solution of Hydrogen Peroxide.

Abstract: Methods for treating mammals for neurointoxication are provided comprising treating the mammal with a xenon-containing gas. Methods of providing neuroprotection in mammals are also disclosed comprising administering therapeutically effective amounts of xenon, preferably in combination with pharmaceutically acceptable carriers, diluents or excipients.

Abstract: A method for treating a patient comprising: (a) injecting into the bloodstream of a patient is breathing a gas mixture having greater than 25% oxygen an aqueous solution comprising: 0.1 to 0.8 M Mg++ and having an osmolarlity less than about 1500 mOSm/l; and (b) increasing the rate of injection at least until the patient feels a sensation of warmth is described.

Abstract: The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit rapid disintegration (less than about 60 seconds) when placed on the tongue or when tested according to USP disintegration testing, while still providing acceptable mouth feel.

Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include a balance of ingredients that allow for the formation of ophthalmic compositions that include an anionic drug and exhibit desired characteristics such as stability, preservation efficacy, desired pH, desired osmolality, combinations thereof or the like.

Abstract: A spray solution generates a foam to sanitize surfaces. The spray dip solution is a mixture of the solution with carbon dioxide and nitrous oxide in a closed vessel. After ejecting the liquid dip solution mixture from a nozzle a foam is generated from the solution as the solution hits a surface. The spray can be applied to a number of different surfaces. In an embodiment of the invention, the spray can be applied to cow teats without risk of cross-contamination of the nozzle or other equipment. The generated foam remains intact on the teat for a prolonged period of time, increases the area of the teat in contact with the foam during the treatment period and disperses skin-conditioning fats present in the dip treatment, thereby increasing the coverage of the skin conditioner on and within the epidermis of the teat and surrounding areas.

Abstract: A spray solution generates a foam to sanitize surfaces. The spray dip solution is a mixture of the solution with carbon dioxide and nitrous oxide in a closed vessel. After ejecting the liquid dip solution mixture from a nozzle a foam is generated from the solution as the solution hits a surface. The spray can be applied to a number of different surfaces. In an embodiment of the invention, the spray can be applied to cow teats without risk of cross-contamination of the nozzle or other equipment. The generated foam remains intact on the teat for a prolonged period of time, increases the area of the teat in contact with the foam during the treatment period and disperses skin-conditioning fats present in the dip treatment, thereby increasing the coverage of the skin conditioner on and within the epidermis of the teat and surrounding areas.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: The present invention provides for a sexual dysfunction compound comprising a rapid-onset pharmaceutical composition that further comprises cocoa powder. The invention also provides for a process for manufacturing the composition, and use of the composition in sexual dysfunction therapy.

Abstract: The present invention refers to a soap kit, preferably liquid, for women's intimate hygiene devised to take into consideration the different phases of the menstrual cycle, keeping the vaginal flora and helping to prevent infection. Besides that, the present invention also refers to a soap composition, preferably liquid, for intimate hygiene, with pH between 3.6 and 4.0 for use during the woman menstrual period. Though the soaps segment in the pharmaceutical market presents a variety of options targeting the woman personal hygiene, these do not take into consideration pH variations seen during the different phases of the menstrual cycle. The objective of the present invention is to provide a kit and a composition of intimate soap for women that can preserve vaginal ecosystem through the different menstrual cycle stages, helping in infection prevention and so reducing chances of irritation processes related to soap not specifically made for this part of the body.

Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Abstract: Provided is a flowable bioresorbable tissue dressing comprising a gas-forming porogen and a gel or gel-forming solution. Also provided is kits for preparing the above-described tissue dressing. Further provided are methods of treating a tissue site of a mammal with the above dressing. Also provided is a reduced pressure delivery system for applying a reduced pressure tissue treatment to a tissue site.

Abstract: A medicinal composition and method to treat or minimize post-ischemic brain cell deterioration that comprises nitrous oxide or a nitrous oxide donor and xenon or a xenon donor. The medicinal composition may be administered prior to or subsequent to a stroke.

Abstract: A two-phase mixture is provided having a dissolved gas and a suspension of bubbles in a liquid. Methods for making, maintaining, and using the two-phase mixture are also provided. The gas molecules may be introduced into the liquid at a high velocity under elevated pressure to form a supersaturated solution that retains the dissolved gas concentration in solution when the solution is exposed to ambient conditions. The mixture may be used in a number of applications where high concentrations of gas must be retained in solution during prolonged exposure to ambient conditions. An example of use is the treatment of wounds to non-surgically remove dead, devitalized, contaminated and foreign matter from tissue cells. The mixture may be combined with a plastic to encapsulate the suspension of bubbles to minimize liberation of the gas bubbles from the mixture.

Abstract: Endothelin-related disorders in mammals can be alleviated by administration to such patients of one or more aliquots of mammalian blood subjected to two or more stressors selected from temperature stressors, electromagnetic emissions and oxidative environments.

Abstract: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for the prophylaxis of impairments of cerebral perfusion and for therapy after cerebral disorders have occurred, irrespective of the cause (e.g. cognitive, sensory or motor in nature).

Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Abstract: A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patient's blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering the aliquot of treated blood to the patient. The treatment can be used on its own or as an adjunctive therapy in combination with conventional CHF treatments.

Abstract: Methods for treating mammals for neurointoxication are provided comprising treating the mammal with a xenon-containing gas. Methods of providing neuroprotection in mammals are also disclosed comprising administering therapeutically effective amounts of xenon, preferably in combination with pharmaceutically acceptable carriers, diluents or excipients.

Abstract: Dry, stable, high available halogen sanitizing granular compositions with a rapid rate of dissolution comprising halogenated 1,3,5-triazine-2,4,6-triones and a dissolution accelerant that is an alkali metal salt of 1,3,5-triazine-2,4,6-trione are disclosed. The disclosed compositions may include inorganic and/or organic disintegration agents. Additionally, these compositions may contain other performance enhancing additives such as water clarifiers, algaestats/algaecides, surfactants, glidants, processing aids, and binders. These UV stable sanitizing compositions contain a high available halogen content, and are stable even when stored in high-humidity environments.

Abstract: A breathing gas mixture is provided for the treatment of lung diseases, containing an amount of perfluorocarbon and oxygen containing 5 vol. % to 40 vol. % of perfluorocarbon relative to the amount of perfluorocarbon and oxygen. The amount of perfluorocarbon and oxygen in the breathing gas mixture ranges from about 20 vol. % to a maximum of 100 vol. % of the breathing gas mixture, and the remaining amount of up to about 80 vol. % contains one or more of the gases nitrogen, nitrogen monoxide and/or one or more anesthesia gases or noble gases, especially xenon. Perfluorohexane is an especially preferred perfluorocarbon.

Abstract: The present application relates to an extruded cosmetic composition, provided in the form of a soft paste, comprising, in a fatty phase, at least one compound having a high melting temperature.The invention also relates to a process for preparing the composition by extrusion.

Abstract: A method of treating headaches that involves generating chilled air, conveying the air to the patient, and inhaling the chilled air until relief is obtained.Apparatus for generating chilled air for the treatment of headaches that includes a heat exchanger located in an insulated housing, a fan for moving air over the heat exchanger, a conduit connected to the housing for conveying the chilled air to a face mask for inhalation by the patient.

Abstract: A process for enriching water with oxygen, wherein water is conducted through a water inlet into a sealed enriching space and through one or more turbulent mixers in the enriching space, open is introduced through an oxygen inlet into the water in the enriching space before passing through the turbulent mixer, and the oxygen-enriched water is recovered. The invention further includes an aerobic process by carrying out a chemical or microbiological reaction in the oxygen enriched water as the reaction medium, and a therapeutic process of carrying out a therapeutic treatment of a body with an agent containing the oxygen enriched liquid as a vehicle. The invention also concerns as apparatus for enriching water with oxygen, having a water inlet, a sealed enriching space containing an oxygen inlet, and one or more turbulent mixers, and an outlet for oxygenated water.

Abstract: The present application relates to an extruded cosmetic composition, provided in the form of a soft paste, comprising, in a fatty phase, at least one compound having a high melting temperature.The invention also relates to a process for preparing the composition by extrusion.

Abstract: A method of treating interstitial cystitis comprising contacting the transitional epithelium lining the urinary bladder and associated structures in a mammal having interstitial cystitis with a solution containing hyaluronic acid having a average molecular weight of not less than 2.times.10.sup.5 Daltons in a concentration effective to treat the interstitial cystitis.

Abstract: A process for enriching a liquid with oxygen by introducing the liquid into an oxygen enriching vessel, subdividing the liquid, subjecting the interior of the vessel to an oxygen pressure of at least about 20 psi, conducting the introduced water in a substantially flowing contact with the oxygen, and recovering the water under oxygen pressure when it is to be bottled. The process is carried out in oxygen enriching apparatus having an oxygen enriching vessel, a number of horizontal trays vertically spaced apart from each other and having a central opening, a liquid supply tube ranging into the interior of the enriching vessel through the central openings, means for discharging liquid from the tube onto a tray, an oxygen supply source for providing the oxygen to the vessel, and a liquid outlet for the removal of the oxygenated liquid. The liquids oxygenated by the invention are used in various aerobic and therapeutic processes.

Abstract: Topical compositions for the treatment of corns, calluses and warts comprising a benzenediol or a substituted 1,2-benzenediol and a pharmaceutically acceptable carrier, are described.

Abstract: Novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful for treating tumors and when used with anti-neoplastic alkylating agents enhance the chemotherapeutic treatment of tumor cells in a host.

Abstract: A method for preparing ibuprofen granulations which exhibit improved stability and resistance to the formation of low melting point eutectics is disclosed. The method includes forging an amalgamation of ibuprofen and an alkali metal in a physical matrix which is suitable for inclusion in a composition without destroying the amalgamation. The stabilized ibuprofen granulation can be combined with other active ingredients and/or excipients to form compositions which have extended shelf life and are resistant to the formation of low melting point eutectics.

Abstract: A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When viral protein is attached to the core particles, the result is a viral decoy which accurately mimics the native virus in both size and structure while being entirely devoid of virulent activity due to the microparticle core. Other antigenic proteins or peptides are attached to provide molecules which are useful in raising antibodies or as a diagnostic tool. Further, pharmacological agents are attached to the microparticles to provide pharmaceutical compositions.

Abstract: Derivatives of melatonin and the pharmaceutically acceptable salts thereof are useful for therapeutically treating hormonally dependent mammalian breast carcinoma. Combination treatments of melatonin derivatives and an antiestrogen compound are especially useful.

Abstract: A make-up cosmetic composition having good oil resistance, water resistance and adhesion, which contains at least one of (a) an organosoluble or a water- and organo-soluble ethyl hydroxyethyl cellulose and (b) an aromatic hydrocarbon resin having a softening point of at least about 120.degree. C.